Ronapreve, a drug used as part of Donald Trump’s medical treatment after he tested positive for the SARS-CoV-2 virus, has been approved in the U.K. The high cost of the monoclonal antibody treatment of £1,000 to £2,000 per session might mean that it will be used for severe cases only. This therapy attacks the coronavirus, and it helps those with a weak immune system.
Can the antibody treatment help Covid-19 positive patients?
According to the companies Regeneron and Roche, monoclonal antibodies attach to the spike protein. The treatment stops the virus from infecting other cells and gives the immune system the time necessary to prepare itself for the infection. Health experts believe the treatment is safe and effective. This is an alternative for the steroid dexamethasone treatment. Due to the high cost, many experts in the U.K believe only those categorized as vulnerable will benefit from it.
AstraZeneca also announced a new antibody therapy
The Oxford company announced that its new antibody therapy can reduce the risk of developing severe Covid-19 symptoms by 77%. The results came after a large-scale trial, and 75% of the research subjects were people with low immune systems. So far, the companies that have released monoclonal antibody treatments are Regeneron, Eli Lilly, GlaxoSmithKline, and Vir. However, the Oxford company AstraZeneca is the first to publish data from a large-scale trial.
A total of 2% of the U.K’s population consists of immunocompromised people. This means that they have suffered an organ transplant or a severe disease such as cancer. By using monoclonal antibody therapy on those with weak immune systems, the hospital systems might become less crowded with patients needing urgent care due to the SARS-CoV-2 virus. The news has been received with great enthusiast by the scientific community.